Affymax, Takeda Recall Anemia Drug

WASHINGTON -- Drug companies Affymax Inc. ( AFFY) and Takeda Pharmaceutical Co. ( TKPYY) have issued a recall of their anemia drug Omontys after reports of severe allergic reactions in some kidney dialysis patients, including some deaths.

The companies said that more than 25,000 patients have received Omontys, which is used against anemia in patients undergoing kidney dialysis.

The companies said that 0.2% of the patients who have received the drug, or about 50, have reported severe allergic reactions and around 0.02% of patients, or about five, have died following their first dose of the drug.

The serious hypersensitivity reactions occur within 30 minutes of the drug being administered for the first time. The companies said that no such reactions have been reported subsequent times that the drug is administered to a patient.

The companies said that dialysis centers should stop using Omontys and that customers will be provided with instructions on how to return the product to the manufacturer for a refund.

Customers with questions can call 1-855-466-6689 from 9:00 a.m. to 5:00 p.m. EST Monday through Friday. The two companies said they were working with the U.S. Food and Drug Administration on the details of the recall.

Copyright 2011 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

More from Stocks

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Neel Kashkari: The Heart of Our Financial System Is More Radioactive Than Ever

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Finding Stocks Right for You: Cramer's 'Mad Money' Recap (Friday 8/25/18)

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Flashback Friday: Amazon, Chip Stocks, Memorial Day

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain